IPP Bureau

IMCD expands its Pharmaceuticals Technical Centre in Jakarta
IMCD expands its Pharmaceuticals Technical Centre in Jakarta

By IPP Bureau - November 23, 2024

The centre features a cutting-edge climatic chamber for stability testing and spectrophotometry to ensure that products meet the most stringent manufacturing and testing standards

Merck recommends rejection of TRC Capital’s “Mini-Tender” Offer
Merck recommends rejection of TRC Capital’s “Mini-Tender” Offer

By IPP Bureau - November 23, 2024

The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024

JHU signs MoU with Ajit Isaac Foundation to bring essential palliative care services to rural India’s terminally ill
JHU signs MoU with Ajit Isaac Foundation to bring essential palliative care services to rural India’s terminally ill

By IPP Bureau - November 22, 2024

The collaboration offers opportunities for training, research fellowships, workshops and conferences at palliative care centers managed by Ajit Isaac Foundation

Sartorius Stedim Biotech opens center for bioprocess innovation in USA
Sartorius Stedim Biotech opens center for bioprocess innovation in USA

By IPP Bureau - November 22, 2024

New research labs and process development services to enable next generation therapeutics

Strides Pharma Science appoints Dr. C. Muthulingam as Executive VP - R&D
Strides Pharma Science appoints Dr. C. Muthulingam as Executive VP - R&D

By IPP Bureau - November 22, 2024

Dr. Muthu was last associated with Mankind Pharma

Merck Life Science India ink MoU with GeNext Genomics
Merck Life Science India ink MoU with GeNext Genomics

By IPP Bureau - November 22, 2024

Genext Genomics can now offer comprehensive solutions that support the growth of India’s biotech ecosystem

Azenta obtains regulatory approval for clinical long-read whole genome sequencing test
Azenta obtains regulatory approval for clinical long-read whole genome sequencing test

By IPP Bureau - November 22, 2024

Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory

Converge Bio raises $5.5M Seed to speed up drug discovery and development with Generative AI
Converge Bio raises $5.5M Seed to speed up drug discovery and development with Generative AI

By IPP Bureau - November 22, 2024

Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion

Siegfried opens global R&D Center for Drug Substances in Switzerland
Siegfried opens global R&D Center for Drug Substances in Switzerland

By IPP Bureau - November 21, 2024

The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth

Emcure and MS Dhoni drive India’s fight against Anemia
Emcure and MS Dhoni drive India’s fight against Anemia

By IPP Bureau - November 21, 2024

Emcure has launched an awareness campaign to help spread the word about male anemia

Informa Markets in India set to host 17th edition of CPHI & PMEC India Expo
Informa Markets in India set to host 17th edition of CPHI & PMEC India Expo

By IPP Bureau - November 21, 2024

CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof

Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development
Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development

By IPP Bureau - November 21, 2024

Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer

European Commission approves Pfizer’s HYMPAVZI for treatment of severe Hemophilia A or B without inhibitors
European Commission approves Pfizer’s HYMPAVZI for treatment of severe Hemophilia A or B without inhibitors

By IPP Bureau - November 21, 2024

HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors

Briefs: Jagsonpal Pharmaceuticals, Dr. Reddy’s Laboratories and Akums Drugs and Pharmaceuticals
Briefs: Jagsonpal Pharmaceuticals, Dr. Reddy’s Laboratories and Akums Drugs and Pharmaceuticals

By IPP Bureau - November 20, 2024

Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities

Lupin receives USFDA approval for mixed salts of a single-entity amphetamine ER capsules
Lupin receives USFDA approval for mixed salts of a single-entity amphetamine ER capsules

By IPP Bureau - November 20, 2024

The product will be manufactured at Lupin’s Somerset facility in the US

Latest Stories

Interviews

Packaging